Pegloticase
![Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set](http://data.docslib.org/img/264x/135084d885a0ce0d8ef8f9f83426c79a.webp)
Top View
- Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: an Evidence-Based Update
- 129-5-1. Prior Authorization. (A) Any Medical Service May Be Placed by The
- Gpi Drug Classification Report
- Clinical Policy: Pegloticase (Krystexxa) Reference Number: ERX.SPMN.221 Effective Date: 01/17 Coding Implications Last Review Date: Revision Log
- Gout and Osteoarthritis: What Works and What Doesn't?
- Gout Guideline Supplementary Appendix 6 – Network Meta
- Pegloticase (Krystexxa) Reference Number: ERX.SPA.197 Effective Date: 01.11.17 Last Review Date: 11.17 Revision Log
- ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
- National Medicines Information Centre
- ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
- Krystexxa (Pegloticase)
- Krystexxa (Pegloticase) NOTICE
- Australian Statistics on Medicines 2009
- New Developments in Gout Conflict of Interest Declaration Objectives
- KRYSTEXXA Safely and Effectively
- XANTHINE OXIDASE INHIBITORY ACTIVITY of Pandanus Amaryllifolius Roxb
- Krystexxa® (Pegloticase)
- Pegloticase (Krystexxa )